Stryker Corporation logo

Stryker Corporation (SYK)

Market Open
5 Dec, 18:44
NYSE NYSE
$
364. 25
-0.1
-0.03%
$
141.94B Market Cap
43.11 P/E Ratio
3.2% Div Yield
474,470 Volume
10.41 Eps
$ 364.35
Previous Close
Day Range
364.14 368.24
Year Range
329.16 406.19
Want to track SYK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days
Stryker's (SYK) Pangea System to Enhance Plating Solutions

Stryker's (SYK) Pangea System to Enhance Plating Solutions

Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.

Zacks | 1 year ago
Medical Technology Stock Benefits from Rising Acute Care Demand

Medical Technology Stock Benefits from Rising Acute Care Demand

Medical and surgical products manufacturer Stryker Co. NYSE: SYK is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive hospital-based emergency services that often occur in the emergency department (ED) or intensive care unit (ICU).

Marketbeat | 1 year ago
Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Zacks | 1 year ago
Stryker: Wait For A Better Entry Point Post-Q2 Results

Stryker: Wait For A Better Entry Point Post-Q2 Results

Stryker is a global medical products and devices company that has global operations in over 75 countries. Historically, the company has been a compounder, generating high returns on capital and has put up impressive top and bottom line growth rates. Recent second quarter results showed strong growth in orthopedics and international markets, with a beat on both revenue and EPS.

Seekingalpha | 1 year ago
Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics

Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Zacks | 1 year ago
Are Medical Stocks Lagging Stryker (SYK) This Year?

Are Medical Stocks Lagging Stryker (SYK) This Year?

Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.

Zacks | 1 year ago
Stryker Corporation (SYK) Q2 2024 Earnings Call Transcript

Stryker Corporation (SYK) Q2 2024 Earnings Call Transcript

Stryker Corporation (NYSE:SYK ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JP Morgan Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Shagun Singh Chadha - RBC Matthew Miksic - Barclays Steve Lichtman - Oppenheimer Vijay Kumar - Evercore ISI Matthew Taylor - Jefferies Joshua Jennings - TD Cowen Danielle Antalffy - UBS Michael Matson - Needham Caitlin Cronin - Canaccord Jayson Bedford - Raymond James Andrew Ranieri - Morgan Stanley David Roman - Goldman Sachs Operator Welcome to the Second Quarter 2024 Stryker Earnings Call. My name is Luke, and I'm your operator for today's call.

Seekingalpha | 1 year ago
Stryker beats Q2 profit estimates on robust demand for medical devices, implants

Stryker beats Q2 profit estimates on robust demand for medical devices, implants

Stryker Corp posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries.

Reuters | 1 year ago
Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

Stryker (SYK) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.54 per share a year ago.

Zacks | 1 year ago
Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 1 year ago
Stryker (SYK) Completes Artelon's Acquisition to Boost Business

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

Zacks | 1 year ago
Loading...
Load More